Axon Enterprise (NASDAQ:AXON) Director Jeri Williams Sells 629 Shares

Posted by on Jun 3rd, 2026

Axon Enterprise, Inc (NASDAQ:AXON – Get Free Report) Director Jeri Williams sold 629 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $469.64, for a total transaction of $295,403.56. Following the transaction, the director owned 1,141 shares of the company’s stock, valued at $535,859.24. This trade represents a 35.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jeri Williams also recently made the following trade(s):

  • On Tuesday, March 17th, Jeri Williams sold 157 shares of Axon Enterprise stock. The stock was sold at an average price of $490.00, for a total transaction of $76,930.00.

Axon Enterprise Trading Up 2.8%

NASDAQ AXON opened at $490.12 on Wednesday. The stock has a market capitalization of $39.50 billion, a PE ratio of 196.84, a price-to-earnings-growth ratio of 8.67 and a beta of 1.45. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. Axon Enterprise, Inc has a 52 week low of $339.01 and a 52 week high of $885.91. The firm has a 50 day moving average of $407.02 and a two-hundred day moving average of $493.35.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.47 EPS. As a group, research analysts expect that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Citizens Jmp reduced their price objective on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating for the company in a research report on Thursday, May 7th. The Goldman Sachs Group set a $535.00 price objective on shares of Axon Enterprise in a research report on Thursday, May 7th. Robert W. Baird set a $800.00 price objective on shares of Axon Enterprise in a research report on Wednesday, February 25th. Royal Bank Of Canada reduced their price objective on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research report on Wednesday, February 25th. Finally, Needham & Company LLC reduced their price objective on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $712.75.

Read Our Latest Report on Axon Enterprise

Institutional Trading of Axon Enterprise

Several institutional investors and hedge funds have recently bought and sold shares of AXON. Brighton Jones LLC purchased a new stake in Axon Enterprise in the 4th quarter valued at $480,000. NewEdge Advisors LLC raised its position in Axon Enterprise by 41.1% in the 1st quarter. NewEdge Advisors LLC now owns 2,294 shares of the biotechnology company’s stock valued at $1,207,000 after purchasing an additional 668 shares during the last quarter. Empowered Funds LLC raised its position in Axon Enterprise by 8.4% in the 1st quarter. Empowered Funds LLC now owns 2,028 shares of the biotechnology company’s stock valued at $1,067,000 after purchasing an additional 157 shares during the last quarter. Woodline Partners LP raised its position in Axon Enterprise by 40.6% in the 1st quarter. Woodline Partners LP now owns 6,932 shares of the biotechnology company’s stock valued at $3,646,000 after purchasing an additional 2,003 shares during the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in Axon Enterprise in the 2nd quarter valued at $284,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Featured Stories

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.